Author/Editor     Rožman, Samo; Novaković, Srdjan; Grabnar, Iztok; Cerkovnik, Petra; Jezeršek Novaković, Barbara
Title     The impact of FcyRIIa and FcyRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
Type     članek
Vol. and No.     Letnik 11, št. 5
Publication year     2016
Volume     str. 3332-3336
ISSN     1792-1074 - Oncology letters
Language     eng
Abstract     Rituximab is a monoclonal antibody routinely used in the treatment of B-cell nonyHodgkin lymphomas. It mediates antibody-dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcy receptors (FcyR) on effector cells. Several polymorphisms in the FcyR genes have been identified to influence rituximab binding to FcyR, thus altering its antitumor effect in indolent lymphomas. In the present study, the impact of FcyRIIa and FcyRIIIa polymorphisms on the survival and response to immunochemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone was evaluated in diffuse large B-cell lymphoma (DLBCL) patients. A total of 29 Slovenian DLBCL patients were studied. Genotyping was conducted for FcyRIIa-27, FcyRIIa-131, FcyRIIIa-48 and FcyRIIIa-158 polymorphisms. The median follow-up time was 29.7 months (range, 9.7-45.4 months). No significant impact of the genotypes was observed on the treatment response, progression-free or overall survival of DLBCL patients. There was a non-significant trend of an improved response to chemotherapy without additional irradiation in patients homozygous for Val at FCyIIIa-158 compared to Phe carriers. The findings of the present study indicate that FcyR polymorphisms have no influence on the survival of DLBCL patients.
Keywords     rituksimab
genetski polimorfizem
limfomi
kemoterapija
rituximab
genetic polymorphism
lymphoma
chemotherapy